Rocket Doctor AI: The $2M NIH Validation That Could Change Everything

This article is disseminated by Rocket Doctor AI

US OTC: AIRDF | Canada: AIDR

Three months ago, I told you in my opinion Rocket Doctor AI had everything needed to become a multi-dollar stock. Today, as a key partner in a $2 million NIH grant, explosive chart momentum, and a SaaS platform scaling faster than I anticipated, I’m more convicted than ever.

This isn’t a trade for me anymore. Barring any major unforeseen issues, Rocket Doctor AI has earned a permanent spot in my portfolio. Here’s why.

The NIH Grant: Federal Validation of What We Already Knew

On October 15th, Rocket Doctor AI announced that its U.S. subsidiary, Treatment.com Inc., in partnership with Rush River Research, secured a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Minority Health and Health Disparities (NIH).

Let me be clear: this isn’t just money. This is federal endorsement of Rocket Doctor’s AI technology after a brutally competitive peer-review process involving over 20 experts.

Here’s what the grant funds:

• $500,000+ to Treatment.com Inc. to strengthen the Global Library of Medicine (GLM) and, in collaboration with Rush River Research, advance the use of family health history as a vital tool for improving population and family health outcomes.

• $1.5 million to Rush River Research, an engineering partner with deep expertise in software development and medical technology project management, recognized for guiding complex health innovation projects from concept to product.

• A two-year project developing AI-powered family medical history tools to improve early diagnosis and preventive care

Phase II grants are rare. They only come after proving success in Phase I. This is the NIH saying: “Your technology works. Now scale it.”

Watch my full interview with Dr. Kevin Peterson, Chief Medical Officer, here:

Why This Grant Matters More Than the Dollar Amount

The NIH doesn’t fund vaporware. They fund clinically validated, commercializable technology that solves real problems.

Rocket Doctor AI’s GLM is not a probabilistic AI that hallucinates. It’s physician-curated medical knowledge built over 9 years, covering:

• 1,000+ diseases

• 17,000+ symptoms

• Clinical expertise from hundreds of doctors globally

• Real-time diagnostic recalculation as new patient data emerges

Unlike many generative AI models trained on internet-available data, the GLM was built by doctors, not engineers. It thinks like a physician because it was taught like one, starting with anatomy, clinical presentation, and evidence-based judgment.

Dr. Peterson has been working on this since 2016, initially at the University of Minnesota Medical School. This isn’t a startup pivot story. This is a decade of groundwork finally reaching commercial scale.

The SaaS Platform: Revenue Reality Meets AI Leverage

Here’s where it gets exciting. Rocket Doctor AI isn’t just an AI company, it’s a high-margin SaaS platform already generating revenue.

Q2 2025 Numbers:

• Gross profit margins: ~89%

• 700,000+ patient visits facilitated

• 300+ physicians on the platform

• Contracted coverage across 3 U.S. states + 4 Canadian provinces

Recent Expansion:

✅ Maryland Medicaid + Medicare (2.6M covered lives) ✅ New York: Major insurer partnership (Medicare + Commercial plans) ✅ Mental Health integration expanding from NY to Maryland ✅ 50 pharmacy locations now delivering care ✅ First municipal contract in Alberta for rural access

The Business Model:

• $18 net per U.S. patient visit (Medicaid/Medicare funded)

• Patients pay $0 out of pocket

• Same/next-day access for 90%+ of Medicaid/Medicare patients

• Doctors get autonomy; patients get access; Rocket Doctor takes its cut

This isn’t theoretical. They’re contracted in three states that cover 30+ million Medicaid/Medicare patients (California, New York, and Maryland in case you forgot). And they are in-network with more and more major insurance companies that serve those patients. Full details in this short video: https://youtu.be/rIJiSZZ9wm4

Even modest penetration rates translate to millions in ARR. And with 89% gross margins, this scales beautifully.

The Valuation Disconnect Is Getting Ridiculous

Let’s talk about the elephant in the room. Healthcare AI unicorns are commanding huge valuations with minimal revenue:

• OpenEvidence: ~$3.5B valuation

• Hippocratic AI: $1.64B valuation

• ADA Health: >$600M market cap

Rocket Doctor AI: ~$40M market cap

Read that again.

Rocket Doctor AI has:

✅ Revenue (not just runway)

✅ 89% gross margins (SaaS leverage proven)

✅ NIH validation (federal endorsement)

✅ Physician-curated AI (no hallucinations)

✅ Public listing (liquidity for investors)

Meanwhile, competitors with early revenue and probabilistic AI models that hallucinate are valued 40-80x higher.

Even assigning a fraction of peer multiples to Rocket Doctor’s AI engine alone would exceed the entire current market cap. The SaaS platform generating actual revenue? That would be gravy.

The Chart: Cup & Handle Forming

When I first covered Rocket Doctor AI in June, it was trading at 28¢. Today it’s at 50¢, a clean double.

But look at the 3-month and 1-year charts. A textbook cup and handle pattern is forming with a rim around 75¢.

If it breaks above that level, the measured move projects into the $1.20–$1.50 range. That’s another double from here.

What’s even more telling: when shares from the private placement unlocked last month, the stock didn’t crater. It held strong and actually pushed higher on volume.

That tells me the investors here understand the vision. They’re not flipping for pennies. They’re accumulating for the multi-dollar move ahead.

1 year chart with what looks like a classic cup and handle forming

Why I’m Holding for Years

I don’t say this lightly. Most penny stocks are trades, not investments. But Rocket Doctor AI has earned a permanent spot in my portfolio because:

1. Revenue + AI = Rare CombinationThey’re not choosing between being a SaaS company or an AI company. They’re both. The platform generates cash flow while the AI provides exponential leverage.

2. Federal ValidationThe NIH doesn’t hand out $2M grants to companies with sketchy technology. This is peer-reviewed, clinically validated AI that solves real problems.

3. Massive TAM71+ million Americans on Medicaid alone. Add Medicare, commercial insurance, and international markets (Taiwan, Europe, Middle East, Africa all showing interest), and you’re potentially looking at a global opportunity.

4. Defensible Moat9 years of physician-curated data isn’t something competitors can replicate overnight. The GLM is a proprietary platform that gets stronger with every deployment.

5. Management ExecutionIn three months, they expanded to Maryland, partnered with a major NY insurer, integrated mental health services, and secured NIH funding. This team moves fast.

6. Institutional Discovery AheadRight now, Rocket Doctor AI trades on the US OTC and the Canadian Stock Exchange). Most U.S. institutions don’t even know it exists. When they discover a revenue-generating AI healthcare platform trading at 1/80th of comparable valuations, the re-rating will be violent.

The Risks (Because I’m Always Honest)

No investment is without risk. Here’s what could go wrong:

• Execution Risk: Scaling across multiple states requires flawless operations and regulatory navigation

• Competition Risk: Well-funded competitors could eventually target Medicaid markets

• Market Risk: If healthcare AI valuations compress broadly, all boats sink (though revenue provides downside protection)

That said, I believe the risk/reward here is asymmetric. The downside is cushioned by real revenue and government contracts. The upside? If Rocket Doctor AI captures even a fraction of the market opportunity, we’re looking at a multi-dollar stock.

Bottom Line

In my opinion Rocket Doctor AI is no longer a speculative play. It’s a revenue-generating, federally validated, high-margin SaaS platform with proprietary AI technology trading at a fraction of peer valuations.

The $2M NIH grant isn’t just funding, it’s validation that the technology works and deserves to scale.

The chart is setting up for another leg higher. The fundamentals are strengthening every quarter. And the valuation disconnect versus billion-dollar competitors is glaring.

From 28¢ to 50¢ in three months was just the beginning. With new state contracts, payer partnerships, NIH validation, and AI leverage coming online, I believe Rocket Doctor AI has everything it needs to become a multi-dollar stock.

Barring any major unforeseen issues, I’ll be holding this one for years.

Updates

ADUR - Aduro seems to be printing all-time highs a couple times a week. The NGP should be commissioned in the next few weeks

CISO is back into the 1.40s

SPMEF -People are still sleeping on South Pacific with gold hitting $4200, more on that

CHHYF - Charbone is proving to be worth the wait with production looking to be coming online in a few weeks.

LEEEF has been a Q3 story this whole time and we are getting close, reclassification could still be a major potential catalyst

Stay tuned, I expect to be adding a new company in the next few weeks

Disclaimer

As always, this is not investment advice and I am not an investment advisor. Investing is risky, protect your capital. XO, Penny

A family member of mine owns 45 Degrees.

45 Degrees, Inc (”We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Rocket Doctor AI entered into a contract for $180,000 and 400,000 options at 45 cents Canadian, to provide marketing services for a term of 6 months. We or certain non-arms length parties own shares of Rocket Doctor AI. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.

Forward Looking Statements

This article contains forward-looking statements about Rocket Doctor AI. These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. However, they involve various risks and uncertainties. Actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements. We undertake no obligation to update forward-looking statements except as required by law.